Shigetec is under clinical development by EveliQure Biotechnologies and currently in Phase I for Bacillary Dysentery (Shigellosis). According to GlobalData, Phase I drugs for Bacillary Dysentery (Shigellosis) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Shigetec LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Shigetec overview
Shigetec is under development for the prevention of shigellosis and Enterotoxigenic E. coli (ETEC) which leads to diarrhoeal diseases in travelers. The vaccine candidate is combination of both Shigella strain and ETEC antigens, expressing a tandem repeat of a fusion protein of LTB and an ST toxoid. It is administered through the oral route in the form of liquid solution and suspension. It is being developed based on vaccine technology platform, which is based on a live, genetically attenuated vaccine strain of the bacterium Shigella.
EveliQure Biotechnologies overview
EveliQure Biotechnologies is an biotech company that develops novel vaccines for the prevention of diarrhoeal diseases. The company is headquartered in Vienna, Austria.
For a complete picture of Shigetec’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
